Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jul 21;7(4):416-421.
doi: 10.1093/ehjqcco/qcaa032.

The independent reduction in mortality associated with guideline-directed medical therapy in patients with coronary artery disease and heart failure with reduced ejection fraction

Natasha K Wolfe  1 , Joshua D Mitchell  1 , David L Brown  1
Affiliations
Randomized Controlled Trial

The independent reduction in mortality associated with guideline-directed medical therapy in patients with coronary artery disease and heart failure with reduced ejection fraction

Natasha K Wolfe et al. Eur Heart J Qual Care Clin Outcomes. .

Abstract

Aims: Guideline-directed medical therapy (GDMT) is underutilized in patients with coronary artery disease (CAD). However, there are no studies evaluating the impact of GDMT adherence on mortality among patients with CAD and heart failure with reduced ejection fraction (HFrEF). We sought to investigate the association of GDMT adherence with long-term mortality in patients with CAD and HFrEF.

Methods and results: Surgical Treatment for Ischaemic Heart Failure (STICH) was a trial of patients with an left ventricular ejection fraction ≤35% and CAD amenable to coronary artery bypass graft surgery (CABG) who were randomized to CABG plus medical therapy (N = 610) or medical therapy alone (N = 602). Median follow-up time was 9.8 years. We defined GDMT for the treatment of CAD and HFrEF as the combination of at least one antiplatelet drug, a statin, a beta-blocker, and an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary outcome was all-cause mortality. Assessment of the independent association between GDMT and mortality was performed using multivariable Cox regression with GDMT as a time-dependent covariate. In the CABG arm, 63.6% of patients were on GDMT throughout the study period compared to 66.5% of patients in the medical therapy arm (P = 0.3). GDMT was independently associated with a significant reduction in mortality (hazard ratio 0.65, 95% confidence interval 0.56-0.76; P < 0.001).

Conclusion: GDMT is associated with reduced mortality in patients with CAD and HFrEF independent of revascularization with CABG. Strategies to improve GDMT adherence in this population are needed to maximize survival.

Keywords: Cardiomyopathy; Coronary artery disease; Heart failure; Outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Use of GDMT in the CABG plus medical therapy versus medical therapy alone arms of the Surgical Treatment for Ischemic Heart Failure trial. There was a significant difference in rates of GDMT at hospital discharge or 30 days after enrolment between the two arms. However, at subsequent follow-up, only about two-thirds of patients in both treatment arms were treated with GDMT. CABG, coronary artery bypass grafting.
Figure 2
Figure 2
Effect of GDMT on all-cause mortality in the Surgical Treatment for Ischemic Heart Failure trial. GDMT was associated with significantly reduced mortality at 1 year that was sustained for 10 years. Adjusted hazard ratios with 95% confidence intervals are shown.
See this image and copyright information in PMC

References

    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS. et al.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed) 2016;69:1167. - PubMed
    1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–477. - PubMed
    1. Hiratzka LF, Eagle KA, Liang L, Fonarow GC, LaBresh KA, Peterson ED; Get with the Guidelines Steering Committee. Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the Get With the Guidelines database. Circulation 2007;116:I207–I212. - PubMed
    1. Newby LK, Allen LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER. et al.. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203–212. - PubMed
    1. Borden WV, Redbery RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA.. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 2011;305:1882–1889. - PubMed

Publication types

MeSH terms

Substances